Cynata Therapeutics Limited (CYP.AX)
- Previous Close
0.2100 - Open
0.1950 - Bid 0.2000 x 1582700
- Ask 0.2100 x 3535900
- Day's Range
0.2000 - 0.2100 - 52 Week Range
0.1050 - 0.2300 - Volume
20,743 - Avg. Volume
171,642 - Market Cap (intraday)
37.723M - Beta (5Y Monthly) 0.81
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0900 - Earnings Date Jul 23, 2024 - Jul 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
www.cynata.comRecent News: CYP.AX
Performance Overview: CYP.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYP.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYP.AX
Valuation Measures
Market Cap
37.72M
Enterprise Value
26.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.07
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.62
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-52.45%
Return on Equity (ttm)
-87.15%
Revenue (ttm)
2.4M
Net Income Avi to Common (ttm)
-13.65M
Diluted EPS (ttm)
-0.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
11.17M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.23M
Research Analysis: CYP.AX
Company Insights: CYP.AX
CYP.AX does not have Company Insights